Victory Capital Management Inc. decreased its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 1.9% during the 4th quarter, Holdings Channel reports. The firm owned 18,004 shares ...

Arrowhead Pharmaceuticals, Inc. shines with 19 clinical programs, strategic partnerships, and promising RNAi data. Click for ...

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alnylam Pharmaceuticals, Inc.’s ALNY share price has surged by 11.75%, which has investors questioning if this is right time ...

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) was upgraded by analysts at StockNews.com to a “sell” rating in a ...

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

AstraZeneca (AZ) and Ionis Pharmaceuticals’ Wainzua (eplontersen) has been approved by the European Commission (EC) to treat ...

Ono Pharmaceutical Co. Ltd. struck a licensing deal with Ionis Pharmaceuticals Inc. for sapablursen, which is in phase II trials for polycythemia vera. Under terms, Osaka, Japan-based Ono gains an ...

Ono Pharmaceuticals has secured the global rights to sapablursen, an RNA-targeting therapy by Ionis to treat polycythemia ...

Japanese drugmaker Ono (TYO: 4528) has entered into a license agreement with USA-based Ionis Pharmaceuticals (Nasdaq: IONS) ...

OSAKA, Japan I March 11, 2025 I Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “ONO”) announced that it has ...

Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains ...